What is the prevalence of Fibrodysplasia ossificans progressiva?

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder with a global prevalence estimated at approximately 1 in 1.6 to 2 million individuals. Because many cases remain undiagnosed or misdiagnosed as other conditions, these figures are likely underestimates of the true number of people living with Fibrodysplasia ossificans progressiva worldwide.

How common is Fibrodysplasia ossificans progressiva?

Fibrodysplasia ossificans progressiva is classified as an ultra-rare disease. Epidemiological data suggests a relatively uniform distribution across different ethnic and geographic populations, with no known predilection for specific regions. While the estimated prevalence is 1 in 1.6 to 2 million, the rarity of the condition makes it difficult to track exact numbers, and the global population of patients is estimated to be in the low thousands.

What are the demographic trends of FOP?

Current clinical research into Fibrodysplasia ossificans progressiva indicates the following trends regarding patient demographics:

• Gender Distribution: There is no significant difference in the prevalence or severity of the condition between males and females; both are affected equally.


• Age of Onset: While FOP is a genetic condition present from birth, the characteristic "flare-ups" and onset of heterotopic ossification typically occur during early childhood, often before the age of 10.


• Underdiagnosis: Misdiagnosis is a major hurdle. Many patients are initially misidentified as having aggressive fibromatosis or soft tissue sarcomas, leading to unnecessary and harmful biopsies that can trigger rapid bone growth.

How does the DiseaseMaps community reflect this data?

At DiseaseMaps.org, we currently support a community of 49 people living with Fibrodysplasia ossificans progressiva. This real-world data helps bridge the gap between clinical literature and the lived experience of patients, providing vital insights into the day-to-day challenges of managing this rare condition where patient numbers are so small that large-scale studies are historically difficult to conduct.

Next steps

• Consult with an orthopaedic specialist familiar with the clinical management of Fibrodysplasia ossificans progressiva to avoid trauma-inducing procedures.


• Join the DiseaseMaps.org community to connect with other families and share experiences in managing symptoms.


• Stay informed about global clinical trials and natural history studies via the IFOPA (International FOP Association) to learn about emerging research.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Fibrodysplasia ossificans progressiva.


• Orphanet: Prevalence of rare diseases (ORPHA:337).


• OMIM (Online Mendelian Inheritance in Man): #135100 - Fibrodysplasia ossificans progressiva.


• International FOP Association (IFOPA): Clinical resources and patient registry data.